Jupiter Neurosciences EBIT Margin 2023-2025 | JUNS

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Profit Margins Gross Margin Operating Margin EBITDA Margin Pre-Tax Margin Net Margin

Jupiter Neurosciences ebit margin from 2023 to 2025. Ebit margin can be defined as earnings before interest and taxes as a portion of total revenues

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Profit Margins Gross Margin Operating Margin EBITDA Margin Pre-Tax Margin Net Margin

Jupiter Neurosciences ebit margin from 2023 to 2025. Ebit margin can be defined as earnings before interest and taxes as a portion of total revenues

Related Stocks
Company Name	Market Cap
Chugai Pharmaceutical (CHGCY)	$77B
Zoetis (ZTS)	$70.7B
Takeda Pharmaceutical (TAK)	$47.2B
Daiichi Sankyo, - (DSNKY)	$41.5B
BeOne Medicines - (ONC)	$27.8B
Sandoz Group AG (SDZNY)	$24.6B
Summit Therapeutics (SMMT)	$19.2B
Merck (MKKGY)	$17.3B
Shionogi (SGIOY)	$14.3B
United Therapeutics (UTHR)	$13.5B
Neurocrine Biosciences (NBIX)	$13.4B
Orion OYJ (ORINY)	$11.1B
IPSEN (IPSEY)	$10.3B
Stevanato Group S.p.A (STVN)	$7.9B
Corcept Therapeutics (CORT)	$7.6B
Madrigal Pharmaceuticals (MDGL)	$7B
Ionis Pharmaceuticals (IONS)	$6.7B
Grifols, S.A (GRFS)	$6.7B
Hikma Pharmaceuticals Plc (HKMPF)	$6.2B
Ono Pharmaceutical (OPHLF)	$5.1B
Soleno Therapeutics (SLNO)	$4B
Hypermarcas (HYPMY)	$3.2B
Crinetics Pharmaceuticals (CRNX)	$3B
Catalyst Pharmaceuticals (CPRX)	$2.7B
AMNEAL PHARMACEUTICALS, INC (AMRX)	$2.6B
NewAmsterdam Pharma (NAMS)	$2.5B
Centessa Pharmaceuticals (CNTA)	$2B
BioCryst Pharmaceuticals (BCRX)	$1.9B
ARS Pharmaceuticals (SPRY)	$1.8B
Ocular Therapeutix (OCUL)	$1.8B